Comparative Pharmacology
Head-to-head clinical analysis: TERRAMYCIN POLYMYXIN versus TERRAMYCIN W POLYMYXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TERRAMYCIN POLYMYXIN versus TERRAMYCIN W POLYMYXIN.
TERRAMYCIN-POLYMYXIN vs TERRAMYCIN W/ POLYMYXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Terramycin (oxytetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA attachment. Polymyxin disrupts bacterial cell membrane permeability by binding to lipopolysaccharides, leading to cell death.
Terramycin (oxytetracycline) is a bacteriostatic tetracycline antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA binding. Polymyxin B is a cationic polypeptide that disrupts bacterial cell membranes by interacting with lipopolysaccharides in Gram-negative bacteria.
Adults: 1-2 drops into affected eye(s) every 4 hours, or 1/2-1 inch ribbon of ointment into conjunctival sac 3-4 times daily. For dermatological use: apply sparingly to affected area 2-3 times daily.
Not applicable: Terramycin (oxytetracycline) and polymyxin B combination is not available for systemic use; topical or ophthalmic preparations only; no standard adult systemic dose.
None Documented
None Documented
Terramycin: 6-10 hours (prolonged in renal impairment); polymyxin B: 6-7 hours (prolonged in renal impairment); clinical context: dosing interval adjustment required for renal dysfunction
Oxytetracycline: 6-10 hours (normal renal function; prolonged to 50-100 hours in anuria). Polymyxin B: 6-8 hours (normal renal function; prolonged to 24-48 hours in renal impairment).
Renal (terramycin: ~70% unchanged in urine; polymyxin B: ~60% unchanged in urine), biliary/fecal (terramycin: ~20-30% in feces; polymyxin B: ~40% fecal elimination)
Renal: Oxytetracycline ~70% unchanged; Polymyxin B ~60% unchanged. Fecal: Oxytetracycline ~20-30% (biliary and unabsorbed); Polymyxin B ~40% (biliary).
Category C
Category C
Topical Antibiotic Combination
Topical Antibiotic Combination